多中心回顾性GUIDANCE001研究:比较经动脉化疗栓塞联合或不联合酪氨酸激酶抑制剂与免疫检查点抑制剂作为不可切除肝细胞癌转化治疗的疗效:中晚期而非早期患者存在生存获益
该多中心回顾性研究比较了单纯TACE(459例)与TACE联合免疫检查点抑制剂和酪氨酸激酶抑制剂(343例)作为不可切除肝细胞癌转化治疗的疗效与安全性。联合治疗组总生存率显著更高(HR 0.43,95%CI 0.35-0.53),中位无进展生存期更长(15.9 vs 8.0个月,p<0.001),但亚组分析仅在中晚期患者中证实获益,早期患者未见获益。联合治疗组肝切除率更高(36.4% vs 23.5%,p<0.001),完全肿瘤缓解率更高(32.1% vs 11.1%,p<0.001),但严重不良事件也更频繁(35.6% vs 27.0%,p=0.009)。
要点
- 中晚期不可切除肝细胞癌患者接受TACE联合免疫检查点抑制剂和酪氨酸激酶抑制剂转化治疗,总生存率显著优于单纯TACE(HR 0.43,95%CI 0.35-0.53)。
- 联合治疗组中位无进展生存期显著更长(15.9 vs 8.0个月,p<0.001),肝切除率更高(36.4% vs 23.5%,p<0.001),完全肿瘤缓解率更高(32.1% vs 11.1%,p<0.001)。
- 联合治疗组严重不良事件发生率显著更高(35.6% vs 27.0%,p=0.009),且亚组分析显示早期患者未见生存获益。
核心结论
- 在中晚期不可切除肝细胞癌患者中,TACE联合免疫检查点抑制剂和酪氨酸激酶抑制剂的转化治疗较单纯TACE与显著更好的生存和转化疗效相关。
研究设计与样本
- 多中心回顾性研究,比较初始不可切除肝细胞癌患者接受单纯TACE(n=459)与TACE联合免疫检查点抑制剂和酪氨酸激酶抑制剂(n=343)作为转化治疗的疗效与安全性。
主要发现
- 联合治疗组较单纯TACE组总生存率显著更高(HR 0.43,95%CI 0.35-0.53)。
- 联合治疗组中位无进展生存期显著更长(15.9 vs 8.0个月,p<0.001)。
- 联合治疗组转化后肝切除率显著更高(36.4% vs 23.5%,p<0.001)。
- 在转化后接受肝切除的患者中,联合治疗组完全肿瘤缓解率显著更高(32.1% vs 11.1%,p<0.001)。
- 联合治疗组严重不良事件发生率显著更高(35.6% vs 27.0%,p=0.009)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Various conversion therapy options have become available to patients with unresectable HCC, but which conversion therapy is optimal for which type of patient is controversial. This study compared the efficacy and safety of TACE alone or combined with immune checkpoint and tyrosine kinase inhibitors. APPROACH AND RESULTS: Data were retrospectively compared for patients with initially unresectable HCC who underwent conversion therapy consisting of TACE alone (n=459) or combined with immune checkpoint and tyrosine kinase inhibitors (n=343). Compared to the group that received TACE alone, the group that received triple conversion therapy showed significantly higher rates of overall survival (HR 0.43, 95%CI 0.35-0.53). In addition, triple therapy was associated with significantly longer median progression-free survival (15.9 vs. 8.0 mo, p <0.001). These results were confirmed in matched subsets of patients from each group. However, subgroup analysis confirmed the results only for patients with HCC in intermediate or advanced stages, not in an early stage. Those who received triple conversion therapy had a significantly higher rate of hepatectomy after conversion therapy (36.4 vs. 23.5%, p <0.001). Among those who underwent hepatectomy after conversion therapy, triple therapy was associated with a significantly higher rate of complete tumor response (32.1 vs. 11.1%, p <0.001). However, it was also associated with a significantly higher frequency of serious adverse events (35.6 vs. 27.0%, p =0.009). CONCLUSIONS: Combining TACE with immune checkpoint and tyrosine kinase inhibitors was associated with significantly better survival and conversion efficacy than TACE alone among patients with intermediate or advanced unresectable HCC.
引用
- Yang DL, Ye L, Zeng FJ, et al. Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages. Hepatology. 2025. PMID: 39908184. doi:10.1097/HEP.0000000000001229
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。